The FDA adds a NAION warning to GLP-1 drugs, plus LEMS clues, Eyedaptic's new Eva AI assistant and a retinal imaging link to AFib.

Jayakrishna Ambati, MD, discusses phase 2 K8 results in GA, its inflammasome mechanism, and dosing designed for convenience.

Hunter Cherwek, MD, of Orbis discusses summit commitments, eye care workforce training, and AI in low-resource settings.

Alfredo A. Sadun, MD, PhD, explains how LEMS mimics myasthenia gravis around the eyes and why its cancer link matters.

Isa S. K. Mohammed, MD, on training refractive surgeons and why lasers make global access harder than for cataract surgery.

Veeral S. Sheth, MD, MBA, FACS, FASRS, discusses the evidence behind the new labeling requirement and how it aligns with the AAO/NANOS consensus statement.

Jayakrishna Ambati, MD, discusses phase 2 K8 findings in geographic atrophy, inflammasome targeting and K8 dosing and delivery.

R. Ross Lakhanpal, MD, FACS, Anu Patel, MD, and Yasha S. Modi, MD, MHS, point to cell replacement in geographic atrophy, care burden, and glycemic control.